chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pain in both arms, chills, pain in neck, lain in left side torso, tremors, body ache.
Information has been received from a physician concerning a 13 year old female who on 05-MAY-1997 and 07-MAY-2001 was vaccinated with the first and second dose of MMR II HSA (lot# not reported). On 14-NOV-2009 (also reported on 30-DEC-2009) the patient experienced mumps. On 16-NOV-2010 the patient had his first blood work and showed: serum measles immunoglobulin M antibody test: negative, serum measles immunoglobulin G antibody test: 6.15 and serum amylase test: 178. On 16-NOV-2010 the patient was diagnosed L parotitis. The patient was afebrile. At the time of the report, the patient's outcome was unknown.
Myalgia, Fever, FATIGUE, ARM PAIN Narrative: STAYED HOME FROM WORK 1 DAY
Dizziness, Arthralgia, FATIGUE, RUNNY NOSE, PAIN/SWELL INJ SITE Narrative:
Onset of S/S was approximately 1200 1/14/2021. Skin reaction with urticaria reaction at injection site.  She became worse within that hour with severe abdominal pain and reported to the ED for care. Rapid COVID test NEG. She is feeling better today 2 days later. Since this reaction is > 48 hours I have asked her to contact the call center and recommended a PCR COVID 19 test
Patient received Monovalent for her booster when according to guidelines started on 09/01/22 she should have received Bivalent. Patient called and informed she can come back in 2 months form last dose to receive Bivalent, undecided will call back to schedule in she wants it.
Initial report was received from a health care professional on 09 April 2012. A 24-year-old female patient had received an injection of MENACTRA, sanofi pasteur Inc. (lot number, route and site not reported) on 06 April 2012 at 3:25 PM. At 4:45 PM, the patient experienced wheezing, dizziness, nausea, shortness of breath and the injection site had redness and itching. The patient was treated with steroid injection and antihistamine. The patient returned to the facility on 09 April 2012 and reported an episode of facial flushing, shortness of breath and drowsiness. It was unknown if the patient had any illness at the time of vaccination. The patient had allergies to Penicillin, BIAXIN, doxycycline, clindamycin and chlorohexagluconate (dentist mouth wash). The patient received no other vaccinations within four weeks of MENACTRA. The patient's outcome was not recovered. Documents held by sender: None.
Patient complains of multiple joint and muscle pains (arms, wrists, shoulders, knees, ankles, and feet): Extreme fatigue with problems sleeping at night and problems with his memory. Additionally, since Nov 2001 he has "developed claustrophobia:. He just recently thought that his problems might be related to the anthrax series when during a briefing this March, he heard another service member who had also received anthrax vaccine, list "the same symptoms that I have". He has received a total of six injections beginning Nov 1998 in conjunction with OPV, TD, Influenza and PPD. He was not ill at the time and notes the following symptoms: "feeling of warmth shooting through my arm" at the injection site for a few minutes after receiving the shot and a little redness that lasted 1-2 days. Denies any nodule or edema. Follow up: continues to have joint pain, arthralgia, difficulty sleeping, myalgias, fatigue and functional impairment.
Swollen lymph node near left clavicle; sore arm, mild rash at injection site
24 hours later nausea, arm soreness, fatigue. 36 hours later body aches, chills, migraine, nausea, arm soreness, chest tightness. 48 hours later migraine, nausea, arm soreness, chest tightness, swollen lymph node under armpit. 4 days after first dose nausea, fatigue, chest tightness, swollen lymph node under armpit.
Patient called the day after his vaccinations to say he was feeling foggy. He stated that when he went to lie down he felt pressure behind his eyes. I called him about 3 hours later and he said that there had been no change. I told him that I would follow up the next day to see how he is doing.
Mini Stroke; Weakness on left side; memory loss; This is a spontaneous report from a contactable consumer (patient). A 48-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE lot number: EW0153) via an unspecified route of administration, administered on the left arm on 20Apr2021 10:30 1st dose, single for COVID-19 immunisation. Medical history included COVID (prior to vaccination), pre-diabetic, anxiety, chest tubes and chest pain. The patient's concomitant medications were not reported. On 29Apr2021 22:00, the patient had a Mini Stroke. Also have weakness on left side and memory loss. The events resulted in Emergency room/department or urgent care visit/hospitalization. The patient was hospitalized for 2 days. Treatment was received for the events which included bloodwork, MRI, CT scan. Since the vaccination, the patient has not been tested for COVID-19. The facility where the vaccine was administered was in a pharmacy or drug Store. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Outcome of the events was not recovered.
Patient had swelling of hands and feet 2 after vaccination administration. Allergic urticaria on face on day 3 after vaccination.
5/12/05 Welt at vaccine site (right thigh). Welt 1x.05 inch with 3 vesicles; afebrile.
78M w progressive met. gastric ca. w. peritoneal carcinomatosis (s/p J-Tube for TF 3/20) on hospice, CKD (s/p kidney tx 2017, on Tac/Pred), initially p/w SBO, ccb worsening ascites (para x2, 9/13, 9/15), COVID, GPC bacteremia/?SBP, transferred for HRF likely 2/2 PNA   Patient with new dry cough overnight 9/12-9/13. Vitals stable on room air. COVID +. CT 15. ID consulted. S/p casirivimab/imdevimab on 9/13. Patient started on Remdesevir on 9/13 (completed 5 day course on 9/17). Given new hypoxia necessitating 2L NC, patient started on Decadron on 9/14 with plan for 10 day course.   PMHx: DMII and HTN78 y.o.male with metastatic gastric cancer originally admitted with SBO and then prolonged hospitalization complicated respiratory failure, bacteremia, COVID 19 (treated with remsdesivir/decadron), and ESRD. Given multiple co morbidities, metastatic disease, and frailty, family decided to transition to CMO.
Tendinitis; Injection site edema; Incorrect administration site/ patient thinks that as Shingrix was injected four inches below the shoulder line, the injection could have missed the deltoid muscle and went straight to the bone.; Bruising/Hematoma at injection site/ experienced bruising at the injection site; Bruising/Hematoma at injection site/ experienced bruising at the injection site; Injection site pain; This case was reported by a physician via call center representative and described the occurrence of injection site bruising in a 68-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 12th August 2019, the patient received the 1st dose of Shingrix. On 12th August 2019, less than a day after receiving Shingrix, the patient experienced injection site bruising, injection site hematoma, injection site pain and vaccine administered at inappropriate site. On 21st January 2020, the patient experienced injection site inflammation and injection site edema. The patient was treated with analgesic, nos (Pain Medication). On an unknown date, the outcome of the injection site bruising and injection site hematoma were resolved with sequelae and the outcome of the injection site pain was not recovered/not resolved and the outcome of the injection site inflammation, injection site edema and vaccine administered at inappropriate site were unknown.   It was unknown if the reporter considered the injection site bruising, injection site hematoma, injection site pain, injection site inflammation and injection site edema to be related to Shingrix.  Additional details were reported as follows: The patient received Shingrix and experienced bruising at the injection site for 1 to 2 days that later turned into a hematoma. The patient also experienced pain at the injection site (left shoulder) that was ongoing at time of reporting. As a measure, the patient received physical therapy, pain medication and consulted a pain specialist. Three weeks before reporting the patient had a shoulder magnetic resonance imaging that showed tendinitis and edema at the injection site. The patient thought that as Shingrix was injected four inches below the shoulder line, the injection might have missed the deltoid muscle and went straight to the bone. The reporter consented to follow up. This is 1 of the 2 cases, reported by same reporter.
Patient developed flushing and rash on his neck. Improved with benadryl. Was monitored for several hours, remained stable, discharged home.
Narrative: Pt became unresponsive after receiving 2nd dose of covid vaccine, leading to ED visit. Pt also completed hemodialysis prior to receiving vaccine. Pt reported feeling tired, lightheaded prior to syncope. On arrival to ED, BP was 80/60 mmHg, given lactated ringers and BP improved. Pt admitted for high risk possible syncopal episode.
delayed injection site reactions; red welts on arm; injection site itch; injection site rash; injection site sore; This spontaneous case was reported by a consumer and describes the occurrence of TYPE IV HYPERSENSITIVITY REACTION (delayed injection site reactions), URTICARIA (red welts on arm), INJECTION SITE PRURITUS (injection site itch), INJECTION SITE RASH (injection site rash) and INJECTION SITE PAIN (injection site sore) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012H20) for COVID-19 vaccination.     The patient's past medical history included No adverse event (NO historical condition not reported.).    On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Feb-2021, the patient experienced URTICARIA (red welts on arm), INJECTION SITE PRURITUS (injection site itch), INJECTION SITE RASH (injection site rash) and INJECTION SITE PAIN (injection site sore). On an unknown date, the patient experienced TYPE IV HYPERSENSITIVITY REACTION (delayed injection site reactions). At the time of the report, TYPE IV HYPERSENSITIVITY REACTION (delayed injection site reactions), URTICARIA (red welts on arm), INJECTION SITE PRURITUS (injection site itch), INJECTION SITE RASH (injection site rash) and INJECTION SITE PAIN (injection site sore) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 20-Feb-2021: No specific follow-up information recorded.
Left-sided neck pain described as 5/10 pain "zinging, burning, aching,"; The pain radiates down the neck to the left upper back/shoulder area, and a few times radiated down neck near injection site in left deltoid; This is a spontaneous report received from a non-contactable reporter(s) (Other HCP).  A 28 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 09Feb2021 14:15 (Lot number: EL3247) at the age of 28 years as dose number unknown, single for covid-19 immunisation. Relevant medical history included: "Eczema" (unspecified if ongoing), notes: Eczema (on hands, feet, knees). The patient took concomitant medications. The following information was reported: NECK PAIN (non-serious) with onset 10Feb2021 07:00, outcome "recovered", described as "Left-sided neck pain described as 5/10 pain "zinging, burning, aching,""; NECK PAIN (non-serious) with onset 10Feb2021 07:00, outcome "recovered", described as "The pain radiates down the neck to the left upper back/shoulder area, and a few times radiated down neck near injection site in left deltoid". The events "left-sided neck pain described as 5/10 pain "zinging, burning, aching,"" and "the pain radiates down the neck to the left upper back/shoulder area, and a few times radiated down neck near injection site in left deltoid" were evaluated at the physician office visit. Therapeutic measures were taken as a result of neck pain, neck pain.
Patient received mixed dose series: 1st dose Pfizer 01/11/2021, second dose Moderna, due to no Pfizer vaccine available. Patient counseled about risks of unknown efficacy mixed dose series and demanded to proceed with Moderna rather than wait for Pfizer availability at unknown time in the future.
I developed I large area around the injection that was fire red and hot to the touch. It was welped up rasied. About the size of 1/2 dollar or little larger and ran down arm little bit too. I also had diarreah.
With the Moderna booster, I had a high fever (101.6), chills, body aches, headache, a very sore right arm and right armpit. I took 2 Tylenol Extra Strength caplets around 9:00 pm and again around 3:00 am. I drank plenty of water and stayed in bed. These symptoms lasted about 24 hours, until about 8:00 pm the next day. I had the same reaction to the second shot too. Two days later, I felt better but my right arm and right armpit still hurt.
lt arm itching @ inj site (deltoid) skin w/erythema & small papular rash;skin warm to touch w/sl swelling;denies pain @ inj site;
Pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Pain) in an elderly female patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) tablet for Rheumatoid arthritis.    No Medical History information was reported.  On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form and UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. On an unknown date, the patient experienced PAIN (Pain). At the time of the report, PAIN (Pain) had not resolved.     The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown.  No concomitant medication information was reported. No treatment medication information was reported. The patient stated that after five hours of taking Rinvoq the pain kicks back and not lasted as long as used to after taking COVID-19 vaccine. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
A few days post-vaccination, patient experienced a fever of 101 degrees f. She was then fine until around 1700 hours on the 14th. Her fever then continued and escalated until around 0130 on 11/15/2001, when she experienced a fever of 103-104 degrees F. she then had a seizure and was transported to the hospital. At the hospital she was treated with Motrin.
11/6/02 Patient complained of red, tender, swollen area left deltoid, erythema, tenderness, swelling noted in approximately 7"x6" area. 11/11/02 13cmx11cm erythema, tenderness right deltoid.
100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again; No Adverse Event; 100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again), PRODUCT STORAGE ERROR (100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again) and NO ADVERSE EVENT (No Adverse Event) in an adult male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 11-Jan-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 11-Jan-2023, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again), PRODUCT STORAGE ERROR (100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown. Not Provided      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessments were provided for POOR QUALITY PRODUCT ADMINISTERED (100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again) and PRODUCT STORAGE ERROR (100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again).    This case contains information for the 32nd out of 100 adult male patients described by the reporter. Concomitant Medication use information was not provided by reporter. Nurse reported that an adverse event 100 bivalent boosters were given yesterday from vials that were put in the fridge and after that refrozen and thawed again. The 100 adult male patients were involved. Moderna COVID19 vaccine bivalent, dosage given in ml unknown to the HCP.  Treatment Medication use information was not provided by reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-697752 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-697752:Master case
Can I give a patient the second dose if it has been more than 6 weeks in between; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a health care professional and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Can I give a patient the second dose if it has been more than 6 weeks in between) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Can I give a patient the second dose if it has been more than 6 weeks in between). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Can I give a patient the second dose if it has been more than 6 weeks in between) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were mentioned. No treatment details were reported.
Information has been received from a registered nurse concerning a male who on 20-June-2008 was vaccinated via subcutaneous route with a first dose of PNEUMOVAX 23 (lot# 655501/1035F), and or DTP vaccine. On 20-June-2008 the patient developed a fever of 103 F and chills later that day. He also experienced redness and swelling at the injection site of the PNEUMOVAX 23 vaccine. The patient sought medical attention via an office visit. The patient was treated with Keflex. On an unknown date, the patient recovered from cellulitis, fever of 103 F, chills, and redness and swelling at the site of injection. No additional information was provided. This is one of several reports received from the same source. Additional information has been requested.
Systemic: Fainting / Unresponsive-Medium, Additional Details: After 10 minutes of getting vaccine pt told observer he was feeling light headed. pt was sipping on water. as we put pt down on back, pt passed out. we checked for pulse and could here pt slowly breathing. gave once dose of 0.3 epi and called 911. emt arrived within 5 minutes and took it from there. pt immediately felt fine after 1 dose of epi. pt bp was stable and hr. emt took care of pt who didnt need to go to hospital
Headache; Hives; Red spot all over; Low grade fever; Site was hurting; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown); via unspecified route of administration in the left arm on 26Mar2021 (at the age 56-year-old) at 09:30 as a single dose for COVID-19 immunisation. Medical history included tachycardia, diabetes type 2, asthma, allergy to mold and bee stings. The patient was allergic to pseudoephedrine and Aavelox. Concomitant medication included atenolol (MANUFACTURER UNKNOWN) and budesonide and formoterol fumarate (SYMBICORT) for unknown indication. The patient did not receive any other vaccine within four weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 12:30, the patient experienced headaches, hives, red spots all over, low grade fever and it was also reported that site was hurting. The treatment medication involved the usage of Benadryl. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care visit. The clinical outcome of events headache, hives, red spots all over, low grade fever and site was hurting was resolving at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
This spontaneous report as received from a healthcare worker refers to an unspecified patients of unknown age and gender. The patient's concurrent conditions and medical history was not reported. On an unspecified dates, an unspecified number of patients received an improperly stored dose of GARDASIL 9 with lot # L048237 and expiration date 08-MAY-2017; lot# L04475 and expiration date 12-MAY-2017; lot # L011846 and expiration date 16-JUN-2017; lot # L016428 and expiration date 30-JUL-2017; lot# L016429 and expiration date 09-AUG-2017; (strength, dose number, dosage and route unspecified). No adverse effect reported. No product quality complaint (PQC) was involved. No further details provided. This is one of two reports received from the same reporter. Additional information has been requested.
approx 20 min p/leaving office, parents noted pt to be pale, floppy, gorggy; this lasted until approx 1030PM when returned to nl color & activity; then slept a long time & appeared fine to mom following morning;
First dose 31MAR2021. Sore arm for a day.; Headache 12APR2021 lasted all week; This is a spontaneous report from a contactable consumer (patient). A 70-years-old female patient received first dose of BNT162B2 (BNT162B2, Solution for injection, Lot number was not reported), via an unspecified route of administration on 31Mar2021 at single dose for COVID 19 immunization. The patient medical history and concomitant medications was not reported. The patient experienced first dose 31mar2021 and had sore arm for a day and headache 12apr2021 lasted all week. Spoke to Cardiologist, just began blood thinner and changed blood thinner medication. Today the headache does not seem as bad maybe a little duller. Started to take Tylenol as therapeutic measures, as a result of first dose 31mar2021. The outcome of events was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.